Immune checkpoint inhibitors combined with anti‐angiogenic therapy as second‐ or further‐line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers

Ähnliche Einträge

• Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis
  von: Akinari Tsukada, et al.
  Veröffentlicht: (2024)
• Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients
  von: Débora Maria Porto, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
  von: Chuang Yang, et al.
  Veröffentlicht: (2024)
• Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
  von: Jie Zhao, et al.
  Veröffentlicht: (2024)
• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
  von: Gen Lin, et al.
  Veröffentlicht: (2024)